The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality!

Time: 9:00 AM – 4:30 PM

Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Alison Armour, Founder Curadh pharmaceuticals, CURADH Pharmaceuticals, Amrik Basran, CSO, CURADH Pharmaceuticals, Andreas Goutopoulos, CEO, actithera, Andrew Cittadine, Chief Operating Officer, Monopar Therapeutics, Chandler Robinson, CEO, Monopar Therapeutics, and more